Black Diamond Therapeutics, Inc.

BDTX

Black Diamond Therapeutics, Inc.

BDTX

Insider Sentiment (TTM):

Last Purchase:2023-10-17Last Sale:2025-03-19Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:23,204,053Shares Outstanding:57,233,413Institutional Ownership Pct.:40.54%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	19	30	21	31	30	98	36	23	33	25	56	58
Available For Sale Securities Debt Securities Curr…	91	88	108	105	113	54	62	89	90	90	75	86
Prepaid Expense And Other Assets Current	5	5	4	3	4	3	3	3	4	4	3	3
Assets Current	115	123	132	139	147	156	101	116	127	119	134	147
Property Plant And Equipment Net	0	0	0	1	1	1	1	1	2	2	2	2
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	8	9	9	17	17	18	19	20	21	21	22	23
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	-	0	-
Assets	125	133	143	158	166	176	123	138	150	143	159	172
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	3	1	1	1	3	4	2	1	1	2	1
Accrued Liabilities Current	14	12	15	15	16	14	17	19	18	16	17	14
Liabilities Current	16	15	16	16	17	17	21	21	18	17	20	15
Operating Lease Liability Noncurrent	13	14	15	16	17	18	19	20	21	21	22	23
Liabilities	29	29	31	32	34	35	39	40	39	38	42	38
Commitments And Contingencies	-	-	0	-	-	-	0	-	-	-	0	-
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	580	578	577	576	574	572	570	568	567	540	534	533
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	-0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-484	-474	-465	-450	-441	-431	-487	-471	-456	-436	-417	-398
Stockholders Equity	96	104	112	126	133	142	83	97	111	104	117	134
Liabilities And Stockholders Equity	125	133	143	158	166	176	123	138	150	143	159	172
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	57	57	57	57	57	57	57	57	56	53	52	52
Shares Outstanding	57	57	57	57	57	57	57	57	56	53	52	52

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-18.38%	-37.13%	-35.29%	-	-	-	-	-	-	-	-	-
2025	47.43%	47.43%	48.00%	20.61%	49.12%	72.37%	-4.02%	-34.92%	-34.42%	16.89%	36.53%	-10.05%
2024	-29.19%	-30.96%	-8.15%	21.88%	-15.48%	-40.46%	-18.46%	-32.62%	-23.69%	-15.26%	-16.32%	5.79%
2023	-	-	-	6.91%	-13.81%	-46.85%	23.56%	47.12%	51.83%	33.86%	84.13%	26.46%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.28	8.46	8.42	8.94	8.73	9.24	4.92	5.55	6.87	7.05	6.82	9.76
Quick Ratio	6.98	8.14	8.18	8.72	8.50	9.05	4.79	5.42	6.67	6.84	6.69	9.57
Working Capital	99.55M	108.43M	116.71M	123.45M	129.92M	138.83M	80.60M	94.74M	108.32M	101.95M	114.39M	131.98M
Leverage & Debt
Debt to Equity	0.30	0.27	0.27	0.25	0.25	0.25	0.47	0.42	0.35	0.37	0.36	0.28
Debt Ratio	0.23	0.22	0.22	0.20	0.20	0.20	0.32	0.29	0.26	0.27	0.26	0.22
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.53	0.47	0.44	0.44	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.74	-0.75	0.39	0.38	0.25	0.09	-1.27	-1.29	-1.46	-1.54	-1.88	-1.65
Free Cash Flow Per Share TTM	0.54	-0.59	0.52	-0.56	-0.63	0.22	-1.13	-1.08	-1.24	-1.31	-1.52	-1.47
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	17.89%	16.94%	6.72%	-5.72%	-	-	-	-	-	-
Net Profit Margin TTM	-	-	31.95%	30.71%	20.63%	7.27%	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-	-	-	-	-	-	-	-	-	-
Net Income Growth (1Y)	-394.72%	-948.77%	-132.10%	-129.41%	-117.93%	-106.38%	-15.48%	-13.09%	-2.67%	-7.79%	-9.57%	-12.34%
EPS Growth (1Y)	-391.83%	-940.32%	-131.06%	-129.19%	-117.41%	-105.83%	-32.49%	-21.65%	-35.56%	-35.07%	-25.27%	-37.46%
Valuation Metrics
P/E TTM	-2.49	-2.82	6.18	10.04	9.76	17.25	-1.69	-3.36	-3.19	-3.29	-1.50	-1.74
P/B TTM	1.10	1.17	1.23	1.71	1.06	0.62	1.41	2.52	2.32	2.52	1.06	1.09
P/S TTM	-	-	1.97	3.08	2.01	1.25	-	-	-	-	-	-
Market Cap	106.13M	121.91M	138.19M	215.76M	140.87M	87.83M	117.76M	245.81M	257.02M	262.67M	123.51M	146.21M
Enterprise Value	86.10M	91.01M	117.20M	184.07M	110.06M	-11.42M	81.32M	221.56M	223.39M	237.25M	67.29M	88.23M
Calculated Values
Free Cash Flow TTM	30.81M	-34.03M	29.61M	-32.06M	-35.54M	12.31M	-62.30M	-61.20M	-68.28M	-67.92M	-66.75M	-74.73M
Net Debt	-20.03M	-30.90M	-20.99M	-31.69M	-30.82M	-99.25M	-36.44M	-24.25M	-33.63M	-25.42M	-56.22M	-57.98M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-03-19Sale

Owner: Biotech, Growth N V, Bb B…

Title: -

Shares: 5,784,292

Price/Share: $2.07

Value: $11,973,484.44

Shares Owned: 2,733,547

Relationship: TenPercentOwner

Ownership: Direct

2024-08-28Sale

Owner: Versant, Voyageurs I Para…

Title: -

Shares: 221,600

Price/Share: $6.32

Value: $1,400,512.00

Shares Owned: 3,726,341

Relationship: TenPercentOwner

Ownership: Direct

2023-10-17Purchase

Owner: Biotech, Growth N V, Bb B…

Title: -

Shares: 400,000

Price/Share: $2.34

Value: $936,000.00

Shares Owned: 8,517,839

Relationship: TenPercentOwner

Ownership: Direct

2023-07-05Purchase

Owner: Ra, Capital Management, L…

Title: -

Shares: 935,850

Price/Share: $5.00

Value: $4,679,250.00

Shares Owned: 3,213,828

Relationship: Director

Ownership: Indirect

2023-07-05Purchase

Owner: Behbahani, Ali

Title: -

Shares: 1,000,000

Price/Share: $5.00

Value: $5,000,000.00

Shares Owned: 4,448,757

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-03-19	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Sale	5,784,292	2.07	$11,973,484.44	2,733,547	4
2024-08-28	Versant, Voyageurs I Para…	TenPercentOwner	-	Direct	Sale	221,600	6.32	$1,400,512.00	3,726,341	4
2023-10-17	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Purchase	400,000	2.34	$936,000.00	8,517,839	4
2023-07-05	Ra, Capital Management, L…	Director	-	Indirect	Purchase	935,850	5.00	$4,679,250.00	3,213,828	4
2023-07-05	Behbahani, Ali	Director	-	Indirect	Purchase	1,000,000	5.00	$5,000,000.00	4,448,757	4
2023-06-30	Bb, Biotech Ag, Biotech G…	TenPercentOwner	-	Direct	Purchase	1,000,000	5.00	$5,000,000.00	8,117,839	4
2023-06-27	Epstein, David M.	Director,Officer	SEE REMARKS	Direct	Sale	25,000	6.70	$167,500.00	671,423	4
2023-06-27	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Purchase	1,740,000	5.49	$9,552,600.00	7,117,839	4
2022-12-22	Ni, Fang	Officer	SEE REMARKS	Direct	Purchase	36,363	1.28	$46,544.64	125,389	4
2022-10-31	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Purchase	99,801	2.25	$224,552.25	5,377,839	4
2022-10-28	Bb, Biotech Ag, Biotech G…	TenPercentOwner	-	Direct	Purchase	172,974	2.18	$377,083.32	5,278,038	4
2022-10-21	Bb, Biotech Ag, Biotech G…	TenPercentOwner	-	Direct	Purchase	87,850	1.51	$132,653.50	4,913,386	4
2022-10-20	Bb, Biotech Ag, Biotech G…	TenPercentOwner	-	Direct	Purchase	53,734	1.42	$76,302.28	4,825,536	4
2022-06-29	Ni, Fang	Officer	SEE REMARKS	Direct	Purchase	25,000	2.44	$61,000.00	69,026	4
2022-04-28	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Purchase	255,711	2.57	$657,177.27	4,694,113	4
2022-04-19	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Purchase	150,000	3.24	$486,000.00	4,288,402	4
2022-04-13	Biotech, Growth N V, Bb B…	TenPercentOwner	-	Direct	Purchase	102,556	3.57	$366,124.92	3,988,402	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

40.54%

Inst. Shares: 23,204,053

Shares Outstanding: 57,233,413

2025-12-31

44.46%

Inst. Shares: 25,281,562

Shares Outstanding: 56,868,111

2025-09-30

48.07%

Inst. Shares: 27,367,840

Shares Outstanding: 56,929,103

2025-06-30

48.99%

Inst. Shares: 27,828,554

Shares Outstanding: 56,803,450

2025-03-31

53.20%

Inst. Shares: 30,147,156

Shares Outstanding: 56,663,798

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	23,204,053	57,233,413	40.54%
2025-12-31	25,281,562	56,868,111	44.46%
2025-09-30	27,367,840	56,929,103	48.07%
2025-06-30	27,828,554	56,803,450	48.99%
2025-03-31	30,147,156	56,663,798	53.20%
2024-12-31	37,301,926	55,028,371	67.79%
2024-09-30	36,493,663	56,507,956	64.58%
2024-06-30	34,319,655	55,155,220	62.22%
2024-03-31	31,613,287	51,808,849	61.02%
2023-12-31	31,338,456	43,954,649	71.30%
2023-09-30	32,328,547	50,943,155	63.46%
2023-06-30	36,965,911	36,516,114	101.23%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Black Diamond Therapeutics, Inc. (BDTX) — SEC Financial Statements & Analysis

Black Diamond Therapeutics, Inc. (BDTX) is a biological products, (no diagnostic substances) company. Black Diamond Therapeutics, Inc. trades on Nasdaq as: BDTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Black Diamond Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.30x, a Price-to-Sales (P/S) ratio of 1.97x (TTM), a Price-to-Book (P/B) ratio of 1.10x (TTM), at a market cap of $106.13M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.30x
P/S TTM: 1.97x
P/B TTM: 1.10x
Market Cap: $106.13M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Black Diamond Therapeutics, Inc. in?

Black Diamond Therapeutics, Inc. (BDTX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is BDTX's market cap?

Black Diamond Therapeutics, Inc. (BDTX) has a market capitalization of $106.13M as of 2026-06-30.

What exchange does BDTX trade on?

Black Diamond Therapeutics, Inc. (BDTX) trades on the Nasdaq.